Atrium Therapeutics, Inc. Common Stock (RNA) — Free Cash Flow Generation Index
Atrium Therapeutics, Inc. Common Stock (RNA) has a Free Cash Flow Generation Index of 0.95x as of December 2023. Free cash flow of $15.64 Million represents 1% of operating cash flow ($16.50 Million). Read Atrium Therapeutics, Inc. Common Stock (RNA) total liabilities for a breakdown of total debt and financial obligations.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Atrium Therapeutics, Inc. Common Stock Free Cash Flow Generation Index (2019–2019)
Historical FCF Generation Index trend for Atrium Therapeutics, Inc. Common Stock across 1 annual periods. Explore Atrium Therapeutics, Inc. Common Stock capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Annual Free Cash Flow Generation for Atrium Therapeutics, Inc. Common Stock (2019–2019)
Year-by-year Free Cash Flow Generation Index for Atrium Therapeutics, Inc. Common Stock. For the full company profile including market capitalisation, see Atrium Therapeutics, Inc. Common Stock market cap and net worth.
| Year | FCG Index | Free Cash Flow (USD) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2019 | 0.91x | $2.25 Million | $2.49 Million | $235.00K | — |